Nicox
| Nicox | |
|---|---|
| legal form | Société Anonyme |
| ISIN | FR0013018124 |
| Seat |
Sophia Antipolis , France
|
| management | Michele Garufi |
| Number of employees | 89 (December 2006) |
| Branch | Biopharmaceutical companies |
| Website | www.nicox.com |
Nicox is a French organic pharmaceutical company based in the Sophia Antipolis science park near Antibes . Its shares are traded on the French stock exchange Euronext in Paris under the symbol COX and are listed in the French CAC Small . The first shareholder is OppenheimerFunds Inc., a subsidiary of the Massachusetts Mutual Life Insurance Company , with 25% of the share capital . The company's market capitalization as of April 2006 was $ 1.2 billion. A research institute is located in Bresso , Italy, Nicox also conducts research on behalf of other pharmaceutical manufacturers such as Merck and Pfizer.
The company deals with the medical use of nitric oxide and is developing an anti-inflammatory drug for the treatment of osteoarthritis , which is comparable to the no longer commercially available preparation Vioxx ® . The market launch is planned for 2010. Drugs for diabetes and heart disease are also being developed. Louis J. Ignarro , a 1998 Nobel Prize winner in Medicine, is a member of the company's Scientific Committee.